Multiple myeloma patients experience high response rate with new three-drug combination. [electronic resource]
Producer: 20100806Description: ii-iii p. digitalISSN:- 1555-8576
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bone Marrow -- pathology
- Boronic Acids -- administration & dosage
- Bortezomib
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Dexamethasone -- administration & dosage
- Disease-Free Survival
- Drug Administration Schedule
- Humans
- Lenalidomide
- Leukocytes -- pathology
- Multicenter Studies as Topic
- Multiple Myeloma -- drug therapy
- Pyrazines -- administration & dosage
- Stem Cell Transplantation
- Thalidomide -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: News
There are no comments on this title.
Log in to your account to post a comment.